Gene therapy restores vision in a canine model of childhood blindness
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
The relationship between the neurosensory photoreceptors and the adjacent retinal pigment epithelium (RPE) controls not only normal retinal function, but also the pathogenesis of hereditary retinal degenerations. The molecular bases for both primary photoreceptor and RPE diseases that cause blindness have been identified. Gene therapy has been used successfully to slow degeneration in rodent models of primary photoreceptor diseases, but efficacy of gene therapy directed at photoreceptors and RPE in a large-animal model of human disease has not been reported. Here we study one of the most clinically severe retinal degenerations, Leber congenital amaurosis (LCA). LCA causes near total blindness in infancy and can result from mutations in RPE65 (LCA, type II; MIM 180069 and 204100). A naturally occurring animal model, the RPE65-/- dog, suffers from early and severe visual impairment similar to that seen in human LCA. We used a recombinant adeno-associated virus (AAV) carrying wild-type RPE65 (AAV-RPE65) to test the efficacy of gene therapy in this model. Our results indicate that visual function was restored in this large animal model of childhood blindness.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since then, AAV-mediated gene delivery into the retina has been used in several proof-of-concept studies to target photoreceptors or the RPE in mice and larger models (such as dogs) [63,64,65].”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [64]
Citations
Cites
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Identification of the gene responsible for Best macular dystrophy
Petrukhin, K., Koisti, M. J., Bakall, B., Li, W., Xie, G., Marknell, T., Sandgren, O., Forsman, K., Holmgren, G., Andreasson, S., et al. (1998) · Nature Genetics · doi:10.1038/915 · Cited by 689
Mutations in RPE65 cause autosomal recessive childhood–onset severe retinal dystrophy
Gu, S.-M., Thompson, D. A., Srikumari, C. R. S., Lorenz, B., Finckh, U., Nicoletti, A., Murthy, K. R., Rathmann, M., Kumaramanickavel, G., Denton, M. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-194 · Cited by 663
Mutations in RPE65 cause Leber's congenital amaurosis
Marlhens, F., Bareil, C., Griffoin, J.-M., Zrenner, E., Amalric, P., Eliaou, C., Liu, S.-Y., Harris, E., Redmond, T. M., Arnaud, B., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-139 · Cited by 606
Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus
Flannery, J. G., Zolotukhin, S., Vaquero, M. I., LaVail, M. M., Muzyczka, N., & Hauswirth, W. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6916 · Cited by 407
Self-citationBiochemistry of visual pigment regeneration: the Friedenwald lecture.
Saari, J. C. (2000) · PubMed · Cited by 270
Simon, A., Hellman, U., Wernstedt, C., & Eriksson, U. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.3.1107 · Cited by 254
Van Hooser, J. P., Aleman, T. S., He, Y.-G., Cideciyan, A. V., Kuksa, V., Pittler, S. J., Stone, E. M., Jacobson, S. G., & Palczewski, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.150236297 · Cited by 252
Self-citationAguirre, G. K., Baldwin, V. J., Pearce‐Kelling, S., Narfström, K. L., Ray, K., & Acland, G. M. (1998) · PubMed · Cited by 244
Self-citationBennett, J., Maguire, A. M., Cideciyan, A. V., Schnell, M., Glover, E., Anand, V., Aleman, T. S., Chirmule, N., Gupta, A. R., Huang, Y., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.17.9920 · Cited by 242
Self-citation
Cited by
Hartong, D. T., Berson, E. L., & Dryja, T. P. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69740-7 · Cited by 2,924
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Self-citationRussell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
Self-citationEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
The current landscape of nucleic acid therapeutics
Kulkarni, J. A., Witzigmann, D., Thomson, S. B., Chen, S., Leavitt, B. R., Cullis, P. R., & van der Meel, R. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00898-0 · Cited by 1,371
Hamel, C. (2006) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-1-40 · Cited by 962
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Self-citationTherapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
Glia–neuron interactions in the mammalian retina
Vecino, E., Rodriguez, F. D., Ruzafa, N., Pereiro, X., & Sharma, S. C. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.06.003 · Cited by 825
Leber congenital amaurosis: Genes, proteins and disease mechanisms
den Hollander, A. I., Roepman, R., Koenekoop, R. K., & Cremers, F. P. M. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.05.003 · Cited by 811
Bi, A., Cui, J., Ma, Y.-P., Olshevskaya, E., Pu, M., Dizhoor, A. M., & Pan, Z.-H. (2006) · Neuron · doi:10.1016/j.neuron.2006.02.026 · Cited by 771
Cideciyan, A. V., Aleman, T. S., Boye, S. L., Schwartz, S. B., Kaushal, S., Roman, A. J., Pang, J.-J., Sumaroka, A., Windsor, E. A. M., Wilson, J. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807027105 · Cited by 673
“We used adeno-associated virus-2-based RPE65 gene replacement therapy to treat three young adults with RPE65-LCA and measured their vision before and up to 90 days after the intervention.”
BackgroundInfluentialSelf-citationJacobson, S. G. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.298 · Cited by 639
“In a canine model of RPE65 deficiency, subretinal delivery of a gene-viral vector agent led to a remarkable activation of retinal and postretinal function.(4,5) Mice”
BackgroundSelf-citationThe Retinal Pigment Epithelium in Health and Disease
R. Sparrrow, J., Hicks, D., & P. Hamel, C. (2010) · Current Molecular Medicine · doi:10.2174/156652410793937813 · Cited by 618
The molecular basis of human retinal and vitreoretinal diseases
Berger, W., Kloeckener-Gruissem, B., & Neidhardt, J. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.03.004 · Cited by 594
Lagali, P. S., Balya, D., Awatramani, G. B., Münch, T. A., Kim, D. S., Busskamp, V., Cepko, C. L., & Roska, B. (2008) · Nature Neuroscience · doi:10.1038/nn.2117 · Cited by 582
High, K. A., & Roncarolo, M. G. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1706910 · Cited by 555
Simonelli, F., Maguire, A. M., Testa, F., Pierce, E. A., Mingozzi, F., Bennicelli, J. L., Rossi, S., Marshall, K., Banfi, S., Surace, E. M., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.277 · Cited by 553
Self-citationGargini, C., Terzibasi, E., Mazzoni, F., & Strettoi, E. (2007) · Journal of Comparative Neurology · doi:10.1002/cne.21144 · Cited by 493
Acland, G. M., Aguirre, G. D., Bennett, J., Aleman, T. S., Cideciyan, A. V., Bennicelli, J., Dejneka, N. S., Pearce-Kelling, S. E., Maguire, A. M., Palczewski, K., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.008 · Cited by 477
“This is also concordant with previous results demonstrating, by genomic PCR, that viral DNA persists only in the neural retina and RPE/ choroid of the injected quadrant [7].”
BackgroundMethodResultInfluentialSelf-citationBennett, J., Wellman, J., Marshall, K. A., McCague, S., Ashtari, M., DiStefano-Pappas, J., Elci, O. U., Chung, D. C., Sun, J., Wright, J. F., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30371-3 · Cited by 461
Self-citationCideciyan, A. V., Jacobson, S. G., Beltran, W. A., Sumaroka, A., Swider, M., Iwabe, S., Roman, A. J., Olivares, M. B., Schwartz, S. B., Komáromy, A. M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218933110 · Cited by 444
“Electroretinogram (ERG) recordings for the first 3 y after treatment were markedly improved for rod and cone amplitudes compared with untreated eyes (34, 35).”
BackgroundMethodSelf-citationRetinal remodeling during retinal degeneration
Jones, B. W., & Marc, R. E. (2005) · Experimental Eye Research · doi:10.1016/j.exer.2005.03.006 · Cited by 428
“Microneuroma expression is more extensive than any model yet seen and is often confluent across large retinal spans.”
BackgroundRetinal Prosthesis for the Blind
Margalit, E., Maia, M., Weiland, J. D., Greenberg, R. J., Fujii, G. Y., Torres, G., Piyathaisere, D. V., O'Hearn, T. M., Liu, W., Lazzi, G., et al. (2002) · Survey of Ophthalmology · doi:10.1016/s0039-6257(02)00311-9 · Cited by 427
Diseases Caused by Defects in the Visual Cycle: Retinoids as Potential Therapeutic Agents
Travis, G. H., Golczak, M., Moise, A. R., & Palczewski, K. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105225 · Cited by 419
High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors
Petrs-Silva, H., Dinculescu, A., Li, Q., Min, S.-H., Chiodo, V., Pang, J.-J., Zhong, L., Zolotukhin, S., Srivastava, A., Lewin, A. S., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.269 · Cited by 398
Self-citationCuenca, N., Fernández-Sánchez, L., Campello, L., Maneu, V., De la Villa, P., Lax, P., & Pinilla, I. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.07.001 · Cited by 401
“retinal degeneration that can cause severe childhood visual loss (Acland et al., 2001; Annear et al., 2013).”
AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
Bennett, J., Ashtari, M., Wellman, J., Marshall, K. A., Cyckowski, L. L., Chung, D. C., McCague, S., Pierce, E. A., Chen, Y., Bennicelli, J. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002865 · Cited by 395
Self-citationAuricchio, A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.26.3075 · Cited by 403
Applications of nanoparticles in ophthalmology
Diebold, Y., & Calonge, M. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.08.002 · Cited by 392
Martin, K. R. G., Quigley, H. A., Zack, D. J., Levkovitch-Verbin, H., Kielczewski, J., Valenta, D., Baumrind, L., Pease, M. E., Klein, R. L., & Hauswirth, W. W. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-1332 · Cited by 362
Self-citationGrimm, D., & Kay, M. (2003) · Current Gene Therapy · doi:10.2174/1566523034578285 · Cited by 350
“A typical example is Leber's congenital amaurosis (LCA), the earliest and most severe form of retinal degeneration.”
BackgroundInfluentialKumaran, N., Moore, A. T., Weleber, R. G., & Michaelides, M. (2017) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2016-309975 · Cited by 334
Otani, A., Dorrell, M. I., Kinder, K., Moreno, S. K., Nusinowitz, S., Banin, E., Heckenlively, J., & Friedlander, M. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421686 · Cited by 342
“Recent advances in gene therapy have led to successful reversal of the retinal degeneration, slow (rds) (8) and retinal degeneration (rd) (9) phenotypes in mice and the RPE65 phenotype in dogs (10) when”
BackgroundX-linked juvenile retinoschisis: Clinical diagnosis, genetic analysis, and molecular mechanisms
Molday, R. S., Kellner, U., & Weber, B. H. F. (2012) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.12.002 · Cited by 331
Cremers, F. P. M., Lee, W., Collin, R. W. J., & Allikmets, R. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100861 · Cited by 315
“As such, extensive efforts over the last 20 years have been devoted to identify a more suitable model system, such as certain breeds of dogs, which have a macula-like “visual streak” that have been efficiently used to study severe retinal degenerations resulting from mutations in the RPE65 gene (Acland et al., 2001; J…”
BackgroundClinical gene therapy using recombinant adeno-associated virus vectors
Mueller, C., & Flotte, T. R. (2008) · Gene Therapy · doi:10.1038/gt.2008.68 · Cited by 313
Various AAV Serotypes and Their Applications in Gene Therapy: An Overview
Issa, S. S., Shaimardanova, A. A., Solovyeva, V. V., & Rizvanov, A. A. (2023) · Cells · doi:10.3390/cells12050785 · Cited by 313
CEP290, a gene with many faces: mutation overview and presentation of CEP290base
Coppieters, F., Lefever, S., Leroy, B. P., & De Baere, E. (2010) · Human Mutation · doi:10.1002/humu.21337 · Cited by 301
“Moreover, the existence of a large animal model such as rdAC is an asset for the implementation of gene-specific therapy for retinal degeneration, as already shown by successful RPE65replacement therapy in Briard dogs that preceded human phase I clinical trials [Acland et al., 2001; Bainbridge et al., 2008; Hauswirth…”
BackgroundBlackshaw, S., Fraioli, R. E., Furukawa, T., & Cepko, C. L. (2001) · Cell · doi:10.1016/s0092-8674(01)00574-8 · Cited by 303
Morphological and Functional Abnormalities in the Inner Retina of the rd/rd Mouse
Strettoi, E., Porciatti, V., Falsini, B., Pignatelli, V., & Rossi, C. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-13-05492.2002 · Cited by 301
Leader of the pack: gene mapping in dogs and other model organisms
Karlsson, E. K., & Lindblad-Toh, K. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2382 · Cited by 298
Stone, E. M. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.08.022 · Cited by 299
Mingozzi, F., Meulenberg, J. J., Hui, D. J., Basner-Tschakarjan, E., Hasbrouck, N. C., Edmonson, S. A., Hutnick, N. A., Betts, M. R., Kastelein, J. J., Stroes, E. S., et al. (2009) · Blood · doi:10.1182/blood-2008-07-167510 · Cited by 295
Correction of the retinal dystrophy phenotype of the RCS rat by viral gene transfer of Mertk
Vollrath, D., Feng, W., Duncan, J. L., Yasumura, D., D'Cruz, P. M., Chappelow, A., Matthes, M. T., Kay, M. A., & LaVail, M. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.221364198 · Cited by 290
An overview of leber congenital amaurosis: a model to understand human retinal development
Koenekoop, R. K. (2004) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2004.04.003 · Cited by 283
Jacobson, S. G., Aleman, T. S., Cideciyan, A. V., Sumaroka, A., Schwartz, S. B., Windsor, E. A. M., Traboulsi, E. I., Heon, E., Pittler, S. J., Milam, A. H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500646102 · Cited by 274
Self-citationRescue of a mitochondrial deficiency causing Leber hereditary optic neuropathy
Guy, J., Qi, X., Pallotti, F., Schon, E. A., Manfredi, G., Carelli, V., Martinuzzi, A., Hauswirth, W. W., & Lewin, A. S. (2002) · Annals of Neurology · doi:10.1002/ana.10354 · Cited by 215
Self-citationScallan, C. D., Jiang, H., Liu, T., Patarroyo-White, S., Sommer, J. M., Zhou, S., Couto, L. B., & Pierce, G. F. (2006) · Blood · doi:10.1182/blood-2005-08-3229 · Cited by 271
Bennicelli, J., Wright, J. F., Komaromy, A., Jacobs, J. B., Hauck, B., Zelenaia, O., Mingozzi, F., Hui, D., Chung, D., Rex, T. S., et al. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300389 · Cited by 267
Self-citationGene therapy rescues cone function in congenital achromatopsia
Komáromy, A. M., Alexander, J. J., Rowlan, J. S., Garcia, M. M., Chiodo, V. A., Kaya, A., Tanaka, J. C., Acland, G. M., Hauswirth, W. W., & Aguirre, G. D. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq136 · Cited by 217
Self-citationA comprehensive review of retinal gene therapy
Boye, S. E., Boye, S. L., Lewin, A. S., & Hauswirth, W. W. (2013) · Molecular Therapy · doi:10.1038/mt.2012.280 · Cited by 262
Self-citationDuan, D., Yue, Y., & Engelhardt, J. F. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0456 · Cited by 262
Beltran, W. A., Cideciyan, A. V., Lewin, A. S., Iwabe, S., Khanna, H., Sumaroka, A., Chiodo, V. A., Fajardo, D. S., Román, A. J., Deng, W.-T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118847109 · Cited by 260
“c, canine; CBA, chicken beta actin promoter (3); h, human; IV, intravitreal control; mOP, minimal opsin promoter.”
InfluentialSelf-citationLund, R. D., Wang, S., Lu, B., Girman, S., Holmes, T., Sauvé, Y., Messina, D. J., Harris, I. R., Kihm, A. J., Harmon, A. M., et al. (2009) · STEM CELLS · doi:10.1634/stemcells.2006-0308 · Cited by 258
Dog star rising: the canine genetic system
Sutter, N. B., & Ostrander, E. A. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1492 · Cited by 258
Functions and Diseases of the Retinal Pigment Epithelium
Yang, S., Zhou, J., & Li, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.727870 · Cited by 252
Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy
Cideciyan, A. V. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.04.002 · Cited by 256
“In the first study (Acland et al., 2001), the threshold to dimmest lights was assayed with luminance-series of ERG b-wave responses which are dominated by the activity of rod bipolar cells summing signals from presynaptic rod photoreceptor cells within their dendritic fields.”
BackgroundMethodInfluentialSelf-citationFunctional and structural recovery of the retina after gene therapy in the RPE65 null mutation dog
Narfstro¨m, K., Katz, M. L., Bragadottir, R., Seeliger, M., Boulanger, A., Redmond, T. M., Caro, L., Lai, C.-M., & Rakoczy, P. E. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-0595 · Cited by 252
Gibbs, D., Kitamoto, J., & Williams, D. S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1130432100 · Cited by 250
Intracellular trafficking of adeno-associated viral vectors
Ding, W., Zhang, L., Yan, Z., & Engelhardt, J. F. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302527 · Cited by 251
AAV cis -regulatory sequences are correlated with ocular toxicity
Xiong, W., Wu, D. M., Xue, Y., Wang, S. K., Chung, M. J., Ji, X., Rana, P., Zhao, S. R., Mai, S., & Cepko, C. L. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821000116 · Cited by 249
Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors
Allocca, M., Mussolino, C., Garcia-Hoyos, M., Sanges, D., Iodice, C., Petrillo, M., Vandenberghe, L. H., Wilson, J. M., Marigo, V., Surace, E. M., et al. (2007) · Journal of Virology · doi:10.1128/jvi.01327-07 · Cited by 246
Neuroprotective strategies for retinal disease
Pardue, M. T., & Allen, R. S. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.02.002 · Cited by 237
“A leading theory is that increased IOP may alter the biomechanical aspects of the posterior globe, leading to increased pressure on the RGC axons as they exit the eye in the optic nerve that then leads to RGC apoptosis (Nguyen and Ethier, 2015).”
InfluentialA 1-Mb resolution radiation hybrid map of the canine genome
Guyon, R., Lorentzen, T. D., Hitte, C., Kim, L., Cadieu, E., Parker, H. G., Quignon, P., Lowe, J. K., Renier, C., Gelfenbeyn, B., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0831002100 · Cited by 243
Bucher, K., Rodríguez-Bocanegra, E., Dauletbekov, D., & Fischer, M. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100915 · Cited by 242
RPE transplantation and its role in retinal disease
da Cruz, L., Chen, F. K., Ahmado, A., Greenwood, J., & Coffey, P. (2007) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2007.07.001 · Cited by 237
Non-viral gene therapy: Gains and challenges of non-invasive administration methods
Foldvari, M., Chen, D. W., Nafissi, N., Calderon, D., Narsineni, L., & Rafiee, A. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.012 · Cited by 238
Immune Responses to AAV in Clinical Trials
Mingozzi, F., & High, K. (2007) · Current Gene Therapy · doi:10.2174/156652307782151425 · Cited by 238
“vector capsid) introduced into the human organism may help to evade immune responses, as will introduction of vector into closed, immunoprivileged sites [ Acland et al., 2001; Kaplitt et al., 2007].”
BackgroundSeeliger, M. W., Grimm, C., Ståhlberg, F., Friedburg, C., Jaissle, G., Zrenner, E., Guo, H., Remé, C. E., Humphries, P., Hofmann, F., et al. (2001) · Nature Genetics · doi:10.1038/ng712 · Cited by 238
Crumbs homolog 1 (CRB1) mutations result in a thick human retina with abnormal lamination
Jacobson, S. G. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg117 · Cited by 235
“We could then assess the relevance to patients with CRB1 mutations of therapeutic strategies emerging for other LCA genotypes (31).”
BackgroundSelf-citationClinical Characteristics and Current Therapies for Inherited Retinal Degenerations
Sahel, J.-A., Marazova, K., & Audo, I. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017111 · Cited by 232
“Proof of concept for gene replacement therapy has been shown by the team of Jean Bennett (Acland et al. 2001) in the Swedish Briard dog, a model of human LCA.”
Biology and therapy of inherited retinal degenerative disease: insights from mouse models
Veleri, S., Lazar, C. H., Chang, B., Sieving, P. A., Banin, E., & Swaroop, A. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.017913 · Cited by 231
“…mouse (Redmond et al., 1998) and a naturally occurring Briard dog model of RPE65 disease were instrumental in developing this treatment, providing the opportunity to examine and prove safety and efficacy of the vectors prior to application in human patients (Acland et al., 2001; Pang et al., 2006).”
BackgroundGene therapy for severe combined immunodeficiency: are we there yet?
Cavazzana-Calvo, M., & Fischer, A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30953 · Cited by 183
Artificial vision: needs, functioning, and testing of a retinal electronic prosthesis
Chader, G. J., Weiland, J., & Humayun, M. S. (2009) · Progress in Brain Research · doi:10.1016/s0079-6123(09)17522-2 · Cited by 226
“In specific cases, long-term experiments on animal models of RP have been very successful (Acland et al., 2001).”
BackgroundSchneider, N., Sundaresan, Y., Gopalakrishnan, P., Beryozkin, A., Hanany, M., Levanon, E. Y., Banin, E., Ben-Aroya, S., & Sharon, D. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101029 · Cited by 224
Basic Biology of Adeno-Associated Virus (AAV) Vectors Used in Gene Therapy
Balakrishnan, B., & Jayandharan, G. (2014) · Current Gene Therapy · doi:10.2174/1566523214666140302193709 · Cited by 225
“Based on in vivo studies, vectors specific to retina (AAV2, AAV4 and AAV5) [64-68], brain (AAV2, AAV5, AAV8, AAV9 and AAVrh10) [69-78], cardiac tissue (AAV1, AAV2, AAV6, AAV8 and AAV9) [79-83], liver (AAV1, AAV2, AAV5, AAV6, AAV7, AAV8, AAV9 and AAV10) [49, 84-93] and lungs (AAV1, AAV2, AAV5 and AAV9) [86-89, 92-98] h…”
Jacobson, S. G., Acland, G. M., Aguirre, G. D., Aleman, T. S., Schwartz, S. B., Cideciyan, A. V., Zeiss, C. J., Komaromy, A. M., Kaushal, S., Roman, A. J., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.005 · Cited by 224
Self-citationEffect of CNTF on retinal ganglion cell survival in experimental glaucoma
Pease, M. E., Zack, D. J., Berlinicke, C., Bloom, K., Cone, F., Wang, Y., Klein, R. L., Hauswirth, W. W., & Quigley, H. A. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3013 · Cited by 222
“The CNTF plasmid(65) expresses a secretory form of human CNTF which has a high affinity for the CNTF receptor , with a hybrid chicken -actin (CBA) promoter and cytomegalovirus (CMV) enhancer element that supports expression in photoreceptors, retinal pigment epithelium, and retinal ganglion cells.(71) The pGFP plasmid…”
MethodSelf-citationWeleber, R. G., Pennesi, M. E., Wilson, D. J., Kaushal, S., Erker, L. R., Jensen, L., McBride, M. T., Flotte, T. R., Humphries, M., Calcedo, R., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.03.003 · Cited by 218
Self-citationRemodeling of second-order neurons in the retina of rd/rd mutant mice
Strettoi, E., Pignatelli, V., Rossi, C., Porciatti, V., & Falsini, B. (2003) · Vision Research · doi:10.1016/s0042-6989(02)00594-1 · Cited by 216
“Some of the restorative approaches cited above are already in the phase of clinical trials; it is reasonable to assume that the efficacy of others will soon reach the levels necessary for experimentation on human patients (Acland et al., 2001).”
BackgroundKong, J., Kim, S.-R., Binley, K., Pata, I., Doi, K., Mannik, J., Zernant-Rajang, J., Kan, O., Iqball, S., Naylor, S., et al. (2008) · Gene Therapy · doi:10.1038/gt.2008.78 · Cited by 215
Bok, D., Yasumura, D., Matthes, M. T., Ruiz, A., Duncan, J. L., Chappelow, A. V., Zolutukhin, S., Hauswirth, W., & LaVail, M. M. (2002) · Experimental Eye Research · doi:10.1006/exer.2002.1176 · Cited by 213
Self-citationEfficient Non-Viral Ocular Gene Transfer with Compacted DNA Nanoparticles
Farjo, R., Skaggs, J., Quiambao, A. B., Cooper, M. J., & Naash, M. I. (2006) · PLoS ONE · doi:10.1371/journal.pone.0000038 · Cited by 208
“Bennett and colleagues used adeno-associated virus to express the RPE65 cDNA which restored retinal function and has successfully persisted over 3 years [18–20].”
MethodLe Meur, G., Stieger, K., Smith, A. J., Weber, M., Deschamps, J. Y., Nivard, D., Mendes-Madeira, A., Provost, N., Péréon, Y., Cherel, Y., et al. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302861 · Cited by 207
den Hollander, A. I., Black, A., Bennett, J., & Cremers, F. P. M. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42258 · Cited by 207
Self-citationPang, J., Chang, B., Hawes, N. L., Hurd, R. E., Davisson, M. T., Li, J., Noorwez, S. M., Malhotra, R., McDowell, J. H., Kaushal, S., et al. (2005) · PubMed · Cited by 227
Self-citationWeber, M., Rabinowitz, J., Provost, N., Conrath, H., Folliot, S., Briot, D., Chérel, Y., Chenuaud, P., Samulski, J., Moullier, P., et al. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00098-4 · Cited by 203
Farrar, G. J. (2002) · The EMBO Journal · doi:10.1093/emboj/21.5.857 · Cited by 203
Molecular genetics of Leber congenital amaurosis
Cremers, F. P. M. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.10.1169 · Cited by 200
“More importantly, a behavioral test demonstrated that the dogs had gained useful vision (88).”
BackgroundVitamin A metabolism in the retinal pigment epithelium: genes, mutations, and diseases
Thompson, D. A., & Gal, A. (2003) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(03)00051-x · Cited by 200
Pang, J.-J., Chang, B., Kumar, A., Nusinowitz, S., Noorwez, S. M., Li, J., Rani, A., Foster, T. C., Chiodo, V. A., Doyle, T., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.09.001 · Cited by 199
Self-citationIn Utero Gene Therapy Rescues Vision in a Murine Model of Congenital Blindness
Dejneka, N. S., Surace, E. M., Aleman, T. S., Cideciyan, A. V., Lyubarsky, A., Savchenko, A., Redmond, T. M., Tang, W., Wei, Z., Rex, T. S., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2003.11.013 · Cited by 197
Self-citationNoninvasive two-photon imaging reveals retinyl ester storage structures in the eye
Imanishi, Y., Batten, M. L., Piston, D. W., Baehr, W., & Palczewski, K. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200311079 · Cited by 194
“Recently, somatic gene therapy and pharmacological intervention were successful in restoration of vision in the dog and mouse animal models of LCA, respectively, with the nonfunctional RPE65 gene (Van Hooser et al., 2000, 2002; Acland et al., 2001).”
BackgroundVitreous: A Barrier to Nonviral Ocular Gene Therapy
Peeters, L., Sanders, N. N., Braeckmans, K., Boussery, K., Van de Voorde, J., De Smedt, S. C., & Demeester, J. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0165 · Cited by 189
AAV hybrid serotypes: improved vectors for gene delivery
Choi, V., McCarty, D., & Samulski, R. (2005) · Current Gene Therapy · doi:10.2174/1566523054064968 · Cited by 191
Zeng, Y., Takada, Y., Kjellstrom, S., Hiriyanna, K., Tanikawa, A., Wawrousek, E., Smaoui, N., Caruso, R., Bush, R. A., & Sieving, P. A. (2004) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.04-0576 · Cited by 191
“Leber congenital amaurosis from mutations in the RPE65 gene is another example.(40) Retinal function in dogs with RPE65 disease improves acutely after treatment, as monitored by ERG recordings after gene delivery.”
Self-citationLeading the way: canine models of genomics and disease
Shearin, A. L., & Ostrander, E. A. (2010) · Disease Models & Mechanisms · doi:10.1242/dmm.004358 · Cited by 187
Sanftner, L. H. M., Abel, H., Hauswirth, W. W., & Flannery, J. G. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0498 · Cited by 187
Self-citation
Metadata
- Authors
- Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., Jacobson, S. G., Hauswirth, W. W., & Bennett, J.
- Affiliations
- Cornell University (US)
- University of Pennsylvania (US)
- University of Florida (US)
- Corresponding author
- Bennett, Jean
- ORCID
- Venue
- Nature Genetics
- Published
- 2001-05
- Volume
- 28
- Issue
- 1
- Pages
- 92-95
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2141354154
- Cited by
- 1,202
- References
- 21
- Citations by year
- 2026: 29 · 2025: 26 · 2024: 19 · 2023: 24 · 2022: 26 · 2021: 38 · 2020: 35 · 2019: 36 · 2018: 39 · 2017: 41 · 2016: 33 · 2015: 40 · 2014: 56 · 2013: 48 · 2012: 64
- FWCI
- 22.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ey011142-05)
- National Eye Institute (EY10820, EY 06855, R01EY010820, EY 11142, R01EY013132, R01EY011123, EY-11123, EY 13132)
- National Institute of Neurological Disorders and Stroke (NS36202)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- gene therapy, Leber congenital amaurosis, RPE65, retinal pigment epithelium, photoreceptors, recombinant adeno-associated virus, childhood blindness, vision restoration, inherited retinal degeneration, large animal model
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Animals, Blindness, Carrier Proteins, Disease Models, Animal, Dog Diseases, Dogs, Eye Proteins, Proteins, Genetic Therapy, Optic Atrophies, Hereditary, cis-trans-Isomerases, Animals, Genetically Modified
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.